Vaxcyte Inc. (PCVX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, PCVX scores 49 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the Fundamental Cash Engine scores 5 of 20 (ROIC -27.6%; FCF yield -6.79%), indicating the weakest contribution to the score. Whale/13F Flow scores 12 of 20 (institutional accumulation and options positioning), Insider Conviction scores 6 of 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 10 of 20 (Beta 1.07; sector sensitivity), and Forensic Balance Sheet scores 16 of 20 (Altman Z 18.11; Piotroski F 4/9; Debt/Equity 0.05).

For a prospective investor, the pattern is that the balance sheet is the strongest pillar while the cash-generation and insider-conviction pillars are weak. Negative ROIC and negative FCF yield mean the business is not currently converting capital into cash returns, so any upside case depends on future catalysts rather than present earnings power. The positive institutional and options signal offsets part of the weakness but does not change the overall distribution-warning verdict. Valuation tradeoffs are visible in the forward P/E of 23 alongside zero trailing EPS, meaning the price relies on expectations not yet reflected in reported earnings.

Per the SEC financials, the company reported no revenue across the three periods and operating losses that widened from $-468.0M in FY 2023 to $-923.7M in FY 2025. Per the market data, operating margin is -33.5%, gross margin and net margin are 0%, and ROIC is -27.6%. Per the Roarable RQD rating, the Altman Z-Score is 18.11, the Piotroski F-Score is 4/9, and Debt/Equity is 0.05, indicating a balance sheet with low leverage despite negative operating cash flow.

Per the recent news feed, the most prominent headline reports the closing of a $1.15 Billion public offering of common stock, pre-funded warrants, and convertible senior notes, including full exercise of underwriters' options. Per the same feed, Guggenheim raised its price target following a vaccine trial win (flagged GREEN), and the stock was reported to hit a new 52-week high. Other items include Investor's Business Daily coverage comparing the company to Pfizer and Merck in a $7 Billion market, and a Seeking Alpha note titled "Vaccine Titan In The Making."

Risk watch items: the $1.15 Billion financing is a dilution and capital-raise event relevant to the negative FCF and the $-669.3M FY 2025 free cash flow. Per the Butterfly Supply-Chain Graph, there are no proprietary signals.

• What are the company's commercial products, revenue model, and any timeline to revenue, given zero reported revenue across all periods?
• What are the terms and dilution impact of the $1.15 Billion offering, including convertible note conversion prices?
• What is the clinical and regulatory pipeline status behind the reported vaccine trial win?
• Why does the source show FY 2023 cash as N/A while reporting $1268.2M in debt, and how does that reconcile with the balance sheet trend?
• What is the basis for the reported trailing EPS of 0 alongside negative net income?